Literature DB >> 7530303

Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents.

A D McLeod1, D R Friend, T N Tozer.   

Abstract

Chronic colitis, e.g., ulcerative colitis and Crohn's disease, is presently treated with glucocorticoids and other antiinflammatory agents. Side effects limit chronic glucocorticoid therapy. The dose, and consequently the side effects, may be reduced by using prodrugs that selectively deliver drug to the colon. We previously synthesized glucocorticoid-dextran conjugates in which dexamethasone and methylprednisolone were attached to dextran (weight-average molecular weight = 72,600) using dicarboxylic acid linkers (succinate and glutarate). In the present study, the hydrolysis kinetics of the hemiesters (hemiester = glucocorticoid+linker) and dextran conjugates were determined after incubation at 37 degrees C in diluted luminal contents of the gastrointestinal (GI) trace of male Sprague-Dawley rats. The hemiesters were rapidly hydrolyzed in the proximal small intestine (e.g., dexamethasone-hemiglutarate t1/2 = 0.5 h). This rate decreased progressively down the GI tract (t1/2 = 4.8, 54, and 68 h in distal small intestine, cecum, and colon, respectively). The enzyme responsible for hemiester hydrolysis, apparently a type-A alkaline carboxylesterase, is probably of host origin because its activity is highest in the small intestine where bacterial count is low. The dextran conjugates resisted hydrolysis in upper GI tract contents but were rapidly degraded in cecal and colonic contents where the bacterial count is high. The dextran conjugate tested, methylprednisolone-succinate-dextran, was easily hydrolyzed by an endodextranase, indicating that substrate specificity is not lost upon the attachment of glucocorticoid. The results of this study indicate that dextran conjugates may be useful in selectively delivering glucocorticoids to the large intestine for the treatment of colitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530303     DOI: 10.1002/jps.2600830919

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Colonic drug delivery: prodrug approach.

Authors:  V R Sinha; R Kumria
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  Colon targeted drug delivery systems: a review on primary and novel approaches.

Authors:  Anil K Philip; Betty Philip
Journal:  Oman Med J       Date:  2010-04

3.  Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity.

Authors:  S L Timofeevski; E F Panarin; O L Vinogradov; M V Nezhentsev
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa.

Authors:  A Lamprecht; U Schäfer; C M Lehr
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

5.  Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting.

Authors:  Yi-Nuo Pang; Yan Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

6.  Light-Triggered Drug Release from Red Blood Cells Suppresses Arthritic Inflammation.

Authors:  Emilia M Zywot; Natalia Orlova; Song Ding; Rishi R Rampersad; Emily M Rabjohns; Victoria A Wickenheisser; Qunzhao Wang; Joshua G Welfare; Lauren Haar; Amanda M Eudy; Teresa K Tarrant; David S Lawrence
Journal:  Adv Ther (Weinh)       Date:  2021-10-13

7.  Synthesis and characterization of methacrylic derivatives of 5-amino salicylic acid with pH-sensitive swelling properties.

Authors:  S Davaran; M R Rashidi; M Hashemi
Journal:  AAPS PharmSciTech       Date:  2001-12-03       Impact factor: 3.246

8.  Polymers for colon targeted drug delivery.

Authors:  H Rajpurohit; P Sharma; S Sharma; A Bhandari
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

Review 9.  Application of three-dimensional printing for colon targeted drug delivery systems.

Authors:  Nitin B Charbe; Paul A McCarron; Majella E Lane; Murtaza M Tambuwala
Journal:  Int J Pharm Investig       Date:  2017 Apr-Jun

10.  Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.

Authors:  Xia-kai He; Zhi-xiang Yuan; Xiao-juan Wu; Chao-qun Xu; Wan-yu Li
Journal:  Theranostics       Date:  2012-11-06       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.